Overview

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Phase:
Phase 2
Details
Lead Sponsor:
Nancy Chan, MD
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Fulvestrant
Pembrolizumab